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Highly Luminescent 2-Phenylpyridine-Free Diiridium Complexes 
with Bulky 1,2-Diarylimidazole Cyclometalating Ligands 
Daniel G. Congrave*, Andrei S. Batsanov
 
 and Martin R. Bryce*
 
While a number of highly emissive dinuclear Ir(III) complexes have been reported, they have generally been restricted to 
structures based on 2-phenylpyridine (Hppy) cyclometalates. We now present a series of new hydrazide-bridged diiridium 
complexes (5–8) which incorporate bulky 1,2-diarylimidazole cyclometalating ligands in the place of Hppy.  Complexes 6–8 
are strongly emissive when doped into poly(methyl methacrylate) (PMMA), displaying the highest PLQYs yet reported for 
ppy-free diiridium emitters (ΦPL = 47–55 ± 10%). Notably, complex 8 has an emission peak at 452 nm and CIExy colour 
coordinates in the sky-blue region (0.18, 0.27), which is competitive with state-of-the-art monoiridium analogues. X-ray 
crystallography and solution-state 19F NMR spectra reveal the presence of rigidifying intramolecular π–π interactions for 
complexes 6–8, which explains their improved photophysical performance compared to 5 which does not have these 
interactions. Structure-property relationships are further rationalised through density functional theory (DFT) and cyclic 
voltammetry (CV) data. All the complexes studied in this work display aggregation induced phosphorescent emission 
(AIPE). This series of compounds increases the structural diversity of highly luminescent dinuclear Ir(III) complexes to 
include luminophoric ligands that are not restricted to Hppy-type fragments. The colour range accessible to AIPE-active 
diiridum complexes has also been substantially broadened.
Introduction 
Iridium(III) complexes have been extensively studied over the 
last 30 years.
1
 The metal-ligand based photochemistry has 
enabled their emission colour to be tuned across the entire 
visible spectrum through modular synthesis.
2
 They typically 
feature high luminescence quantum efficiencies (Φ), 
microsecond-scale phosphorescence lifetimes (τ) and good 
electrochemical stabilities. These properties are advantageous 
for  applications
3
 such as photocatalysis,
4
 biological labelling,
5
 
sensing,
6
 and phosphorescent organic light-emitting devices 
(PhOLEDs)
7,8
 
 
Figure 1. Representative highly emissive diiridium complexes containing 2-phenylpyridine (Hppy) fragments with selected solution photoluminescence 
parameters (all obtained in degassed DCM). 2-Phenylpyridine fragments are highlighted in green.
Interest in phosphorescent dinuclear lr(III) complexes has recently increased. Unlike their mononuclear analogues, they 
feature ligands which bridge the two metal centres. A wide 
variety of bridging ligands has been explored, and they can 
heavily influence the photophysical properties of the 
complexes.
9–22
 For example, flexible bridges impart 
aggregation-induced phosphorescent emission (AIPE) to 
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orange/ red-emitting complexes,
14
 which have been employed 
in sensing applications.
23,24
 Complementarily, bridging ligands 
can lead to rigid complexes, either covalently through the 
incorporation of rigid polyaromatic structures (complexes 1, 2 
and 3, Figure 1),
15,17,18,22,25
 or non-covalently through 
promoting intramolecular perfluoroaryl-aryl π–π interactions 
with peripheral ligands (complex 4, Figure 1).
26
 This has 
allowed the development of diiridium complexes that exhibit 
high solution photoluminescence quantum yields (PLQYs) (> 
ca. 50%) from the red to the sky-blue regions of the visible 
spectrum (e.g. complexes 1–4). Diiridium complexes have also 
demonstrated advantages over their mononuclear 
counterparts. For example, sub-microsecond phosphorescence 
lifetimes are obtained alongside high PLQYs (complexes 1 and 
2) due to high radiative rate constants (kr), which is likely due 
to an improved spin-orbit coupling (SOC) effect exerted by two 
proximal heavy metal atoms.
15,17,25
 Chang and co-workers have 
also recently reported sky-blue diiridium phosphors with unity 
PLQY that are sublimable.
22
 
 2-Phenylpyridine (Hppy)-based cyclometalating ligands 
(Figure 1) are popular for Ir(III) phosphors due to their 
synthetic versatility, well-understood structure-property 
relationships, and because they reliably afford complexes with 
high PLQYs.
27–29
 Consequently, Hppy-type fragments that form 
5-membered cyclometalates have been incorporated into the 
bridging or peripheral ligands of almost all the significantly 
emissive diiridium complexes (PLQY > ca. 30%) reported in the 
literature (e.g. complexes 1–4).
8,9,14,16,18,20,23,25
 In contrast, non-
Hppy components have been seldom explored in diiridium 
complexes. We know of only a single structural type that does 
not contain a Hppy fragment and is significantly emissive at 
room temperature: namely, cationic AIPE complexes featuring 
2-(phenyl)pyrazole (Hppz) cyclometalating ligands which 
exhibit orange/ red emission with PLQYs ≤ 31%.
23,31
 This lack of 
structural diversity is restrictive, especially considering that 
Hppy-based cyclometalating ligands have some drawbacks. For 
example, the synthesis of Hppy-based ligands often requires 
expensive transition metal-catalysed routes.
32
 Also Hppy-
derived sky-blue/ blue emissive Ir(III) complexes suffer from 
poor excited state stability, particularly under PhOLED 
operation.
27
 
 
Figure 2. Structures of the complexes and ligands studied in this work. 
Bulky 1,2-diarylimidazole ligands which form 5-membered 
cyclometalates are very topical as they have afforded highly 
emissive sky-blue mononuclear Ir(III) complexes that are 
notably more stable under PhOLED operating conditions than 
Hppy-functionalised analogues.
27,30,33–38
 They have also been 
incorporated into heteroleptic mononuclear Ir(III) complexes 
that show promising preferential dipole alignment in solution-
processed films.
30
 Beneficially, 1,2-diarylimidazole ligands can 
also be synthesised from readily available starting materials 
through condensation chemistry, avoiding transition metal 
catalysis.
39
 Despite this promise, while 1,2-diarylimidazoles 
have been studied as cyclometalating ligands in homo- and 
heteroleptic monoiridium complexes,
38,40–42
 to the best of our 
knowledge they have not previously been applied to 
phosphorescent diiridium systems. 
 The aim of the present work is to diversify phosphorescent 
dinuclear Ir(III) complexes to include structures that are not 
restricted to Hppy-based ligands. We present a series of new 
diiridium complexes (5–8) (Figure 2) which feature bulky 1,2-
diarylimidazole cyclometalating ligands alongside hydrazide 
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bridging ligands. Density functional theory (DFT) calculations, 
X-ray crystallography and electrochemical data provide further 
insight into their structural and optoelectronic properties. 
 
Results and discussion 
Design, synthesis and characterisation 
The structures of the complexes 5–8 are shown in Figure 2. 
The complexes are of the formula [(Ir(C^N)2)2(O^N^N^O)] with 
C^N = 9–11 and O^N^N^O = 12 and 13. The conjugate acids of 
the ligands in the complexes (H9–H11 and 2H12 and 2H13) are 
also shown in Figure 2. The mesityl-functionalised 1,2-
diarylimidazole cyclometalating ligand H9 was selected due to 
the favourable photophysical properties of its homoleptic 
complex,
30,34
 and because the steric bulk of the mesityl group 
should impart solubility and rigidity without inhibiting the 
formation of the complexes 5–8. The bridging ligands 2H12 
and 2H13 were employed in complexes 5 and 6 to target sky-
blue emission and study the effect of intramolecular π–π 
stacking between the perfluoroaryl groups of 12 and the 
peripheral cyclometalating ligands.
26
 Due to the enhanced 
photophysical performance of 6 compared to 5 (discussed 
below) the perfluoroaryl bridge 2H12 was incorporated into 
complexes 7 and 8, where incremental fluorination of their 
cyclometalating ligands (H10 and H11) blue shifts their 
emission through HOMO stabilisation.  
The bridging ligands 2H12 and 2H13 were synthesised as 
reported.
26
 The cyclometalating ligands H9–H11 were 
accessible on a multi-gram scale following Strassner’s one-pot 
transition metal-free procedure.
39
 The diiridium complexes 5–
8 were then synthesised by cleaving the corresponding μ-Cl 
dimers with the bridging ligands 2H12 or 2H13 under basic 
conditions.
12,13,19,26
 Complexes 6–8 were obtained in ≥ ca. 50%  
yields as diastereomeric mixtures which were not separated, 
apart from complex 5, which was isolated as a single 
diastereomer. This follows literature precedent, where 
incorporation of the bis-trifluoromethyl bridge 2H13 affords 
diastereoselectivity.
26
  
Complexes 5–8 show good thermal stability with 
decomposition temperatures (Td corresponding to 5% weight 
loss) of > 400 °C by thermal gravimetric analysis (TGA) (Figures 
S6–S9). 
 Expansions of the C6F5 regions of the 
19
F {
1
H} NMR spectra 
of complexes 6–8 are shown in Figure 3.  
Figure 3. Expansions of the C6F5 regions of the 376 MHz 
19F {1H} spectra of 6–8 recorded in CDCl3 at 298 K. Diastereomeric ratios from integration: 6 ca. 1:1, 7 
ca. 1:0.6, 8 ca. 1:0.9.  
 
The 
19
F NMR spectra for the diastereomeric mixtures of 6–8 
each display 10 environments in the C6F5 region (5 per 
diastereoisomer). This is greater than the 6 environments that 
would be expected (3 per diastereoisomer) for mono-
substituted perfluorophenyl groups, and is due to a lowering 
of molecular symmetry. This is ascribed to restriction of 
rotation of the bridge C6F5 groups due to intramolecular π–π 
interactions with peripheral cyclometalating ligands (seen in 
the solid state for 7 and 8 in the  X-ray diffraction data 
below).
26,43
 
 
X-ray crystal structures 
The single-crystal X-ray crystal structures of the meso 
diastereomers of 7 and 8 are displayed in Figure 4. Relevant 
parameters are listed in Table 1. Presumably, the meso 
diastereomers preferentially crystallised from solutions of 
diastereomeric mixtures due to their inversion centre 
6 
7 
8 
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symmetry. Meso 7 crystallised as a DCM hexasolvate whereas 
meso 8 crystallised as a MeOH disolvate.  
 
Table 1. Selected geometrical parameters of 7 and 8 (bond distances in Å). 
 meso 7 
•6CH2Cl2 
meso 8 
•2MeOH 
Space group C2/c Pbca 
Mol. symmetry Ci Ci 
Ir centres ΔΛ ΔΛ 
Ir---Ir, Å 5.022 5.065 
Ir–C (trans-O) 2.003(4) 2.003(3) 
Ir–C (trans-N) 2.012(4) 2.016(3) 
Ir–N, stacked 2.020(3) 2.018(2) 
Ir–N, non-stacked 2.019(3) 2.040(2) 
Bridge geometry 
OCNNCO folding, ° planar planar 
Ir displacement, Å 0.086 0.208 
Ir–O 2.119(3) 2.130(2) 
Ir–N 2.144(3) 2.159(2) 
N–N 1.434(4) 1.437(3) 
N–C 1.306(6) 1.305(4) 
C–O 1.279(4) 1.287(3) 
Intramolecular stacking (π–π) 
Θ, °a 3.5 3.0 
D, Å
b
 3.30 3.26 
Centroid–centroid, Å 3.35 3.41 
a Interplanar angle between ring A of the bridging ligand and ring B of the 
cyclometalating ligand (see Figure 4); b distance between the plane of ring B 
and the centroid of ring A. 
 
Figure 4. X-ray molecular structures of meso 7 and meso 8. R = mesityl. 
Thermal ellipsoids are drawn at the 50% probability level, H atoms, 
solvent of crystallisation and some mesityl groups are omitted for 
clarity. Primed atoms are generated by a crystallographic inversion 
centre. Vector D identifies intramolecular – interactions (see Table 
1). 
The Ir centres in both structures display distorted octahedral 
coordination. The N atoms of the two C^N cyclometalating 
ligands occupy axial positions with respect to the bridge plane, 
and are trans to one another.
8,12
 The central hydrazide 
moieties of meso 7 and meso 8 are planar, and the aryl 
substituents (A) on the bridging ligands are oriented 
approximately perpendicular to the hydrazide planes and are 
stacked face-to-face (–) with the phenyl ring (B) of a 
cyclometalating ligand (Figure 4). The stacking is closer and 
more parallel in meso 8 compared to meso 7 (Θ = 3.0 vs. 3.5° Θ 
D = 3.26 vs. 3.30 Å). However, the slightly larger centroid–
centroid distance for meso 8 (3.41 Å vs. 3.35 Å for meso 7) 
indicates greater slippage of the stacked rings. 
 
Electrochemical study 
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6
 
Figure 5. Cyclic voltammograms in 0.1 M n-Bu4NPF6/ DCM showing the 
oxidation processes for complexes 5–8. The current range for each 
voltammogram is 10 – −10 μA. 
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Table 2. Electrochemical data for complexes 5–8 referenced to E1/2 
FcH/ FcH+ = 0.00 V. 
aPeak splitting between Eox(1) and Eox(2). bAll reductions are 
electrochemically irreversible. cHOMO levels calculated from CV 
potentials by HOMO = –4.8 + (–E1/2
ox(1)), using ferrocene as the 
standard. dLUMO levels calculated from CV potentials by LUMO = –4.8 
+ (–Eredonset), using ferrocene as the standard. 
The oxidation and reduction processes for 5–8 were studied by 
cyclic voltammetry (CV). The data are listed in Table 2. The 
oxidative waves are presented in Figure 5 and the reductive 
processes are included in Figure S1. All complexes display two 
oxidation waves.  
Figure 6. Emission spectra for complexes 5–8. (Top) spectra of complexes 
doped into PMMA at 1 wt.% at room temperature. (Bottom) spectra of 
complexes in 2-MeTHF glasses at 77 K (λexc 355 nm). 
 
They are assigned to sequential Ir
3+
/ Ir
4+ 
redox couples and are 
indicative of electronic communication between the two 
centres. Both oxidations are electrochemically reversible for 5–
8 based on the equal magnitudes of the coupled oxidation and 
reduction peaks. All reduction processes are electrochemical 
irreversible.  
The first oxidation potential of 5 is more positive than for 6 
(by 0.04 V). This suggests that the complexed 
bis(trifluoromethyl) bridge 2H13 is more electron withdrawing 
than the bis(pentafluorophenyl) bridge 2H12.
44
 Sequential 
fluorination of the cyclometalating ligands in 6–8 leads to 
successive increases in the first oxidation potentials, as 
expected. The peak splitting between the first and second 
oxidations (ΔE1/2) for the series 6–8 also increases 
incrementally, suggesting that the bridge HOMO contribution 
increases along the series. Complex 5 displays the lowest ΔE1/2. 
This is because the complexed bridge 2H13 has a shorter 
conjugation length than 2H12 and therefore is expected to 
feature a larger energy gap, decreasing its contribution to the 
HOMO of 5. These conclusions are corroborated by the DFT 
data below. 
The reduction onsets for 5–8 are comparable to the values 
for heteroleptic mononuclear complexes functionalised with 2-
arylimidazole ligands.
41
 While the irreversible nature of the 
reductions hinders their accurate determination, there are two 
clear qualitative trends in the data. (i) The reduction potential 
for 5 is less negative than for 6, i.e. 5 is easier to reduce, in-line 
with the more electron-withdrawing complexed bridge 2H13 
and the higher first oxidation potential of 5. (ii) Sequential 
fluorination in the series 6–8 leads to consecutively less 
negative reduction potentials as the complexes become more 
electron poor. However, the LUMO energies do not drop as 
significantly as the HOMO energies upon fluorination, leading 
to sequentially larger electrochemical bandgaps in the order 6 
< 7 < 8. 
 
Photophysical properties 
Table 3. Summary of the key photoluminescence data for complexes 
5–8. 
 Doped into PMMA 1% wt.
a
 2-MeTHF glass
b
 
Complex 
λmax em 
/nm 
[CIExy] 
PLQY 
/% (± 
10%) 
  
/μs 
    
/× 
105 
s
–1
 
     
/× 
105 
s
–1
 
λmax em 
/nm 
(λ10% em 
/nm)c [ET 
/eV]d 
  
/μs 
5 
469sh, 
500 
[0.20, 
0.40] 
11 1.82 0.60 4.89 
466 (458) 
[2.71] 
3.88 
6 
470sh, 
501 
[0.20, 
0.39] 
55 2.80 1.96 1.61 
469 (459) 
[2.70] 
4.02 
7 
456sh, 
486 
[0.18, 
0.31] 
47 4.15 1.13 1.28 
456 (442) 
[2.81] 
5.35 
8 452sh, 52 4.55 1.14 1.05 449sh, 480 5.21 
Complex 
E
ox(1) 
/V 
Epa/ Epc
 
[E1/2] 
E
ox(2) 
/V 
Epa /Epc 
[E1/2] 
ΔE1/2 
/V
a 
E
red
onset
 
/V
b 
HOMO 
/eV
c
 
LUMO 
/eV
d
 
5 
0.38/ 0.29 
[0.34] 
0.65/ 0.55 
[0.60] 
0.26 –2.82 –5.14 –1.98 
6 
0.33/ 0.24 
[0.30] 
0.73/ 0.62 
[0.67] 
0.37 –2.95 –5.10 –1.85 
7 
0.55/ 0.43 
[0.49] 
0.95/ 0.84 
[0.89] 
0.40 –2.89 –5.29 –1.91 
8 
0.72/ 0.63 
[0.68] 
1.18/ 1.05 
[1.12] 
0.44 –2.76 –5.48 –2.04 
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480 
[0.18, 
0.27] 
(440) 
[2.82] 
sh = Shoulder.  aMeasured in an integrating sphere under air using an 
excitation wavelength of 355 nm. bMeasured at 77 K using an excitation 
wavelength of 355 nm. cWavelength at 10% intensity on the blue edge of 
the spectrum obtained at 77 K. dEstimated using ET = hc/ λ10% em.   = 1/     + 
  . 
The absorption spectra of 5–8 are shown in Figure S2 and 
the data are listed in Table S1. The spectra display features 
typical of cyclometalated iridium complexes: There are intense 
bands below ca. 300 nm which correspond to population of LC 
states, while the weaker bands extending to ca. 450 nm are 
assigned to 
1
MLCT and 
3
MLCT transitions.
45,46
 The extinction 
coefficients are higher than for similar mononuclear 2-
phenylimidazole complexes,
41
 ascribed to a larger number of 
cyclometalating ligands and Ir atoms per complex. An increase 
in the intensity of the 
3
MLCT bands compared to mononuclear 
analogues may be due to improved spin-orbit coupling in 
dinuclear complexes.
15,17
 
The emission spectra for 5–8 doped into poly(methyl 
methacrylate) (PMMA) at room temperature, and in 2-MeTHF 
at 77 K are shown in Figure 6. Photoluminescence data are 
tabulated in Table 3. Complexes 5–8 are non-emissive in DCM 
solution at room temperature with PLQYs ≤ 0.05%. In contrast, 
they are emissive (PLQY = 11–55 ± 10%) in the blue-green/ sky-
blue regions at room temperature in dilute PMMA films (1 wt% 
complex). To the best of our knowledge, complexes 6–8 
exhibit the highest PLQYs yet reported for ppy-free diiridium 
complexes (PLQY = 47–55 ± 10%).
23,31
 Sequential fluorination 
of the cyclometalating ligands in the series 6–8 leads to 
incremental blue shifts in their emission, as expected.  We 
note that complex 8 has an emission peak (452 nm) and CIExy 
coordinates (0.18, 0.27) that are competitive with the bluest 
monoiridium analogues that contain arylimidazole ligands.
35,38
 
The comparatively broad emission of 5–8 is reminiscent of 
mononuclear analogues.
27,30,33–38 While we cannot completely 
disregard any effects of diastereomeric mixtures on the 
optoelectronic properties of 6–8, there are literature 
precedents that diiridium diastereomers display very similar 
photophysical properties.
15,25
 
The matrix-dependent emission properties of 5–8 are 
ascribed to non-radiative emission quenching in solution. As 
this is suppressed in a PMMA matrix, it is evident that the 
dominant pathway for non-radiative decay in solution likely 
involves significant molecular motion, rather than any other 
process, for example C–C bond stretching.
47
 There are 
examples of homo- and heteroleptic monoiridium complexes 
functionalised with bulky 1,2-diarylimidazole ligands that are 
highly emissive in solution,
34,37,41
 which indicates that the 
bridging ligands of 5–8 are likely to be the structural feature 
responsible for their non-emissive behaviour in solution. 
Therefore, we conclude that non-radiative decay through 
motion of the bridging ligand is responsible for the quenching 
of solution phosphorescence, which is reinforced by literature 
precedents.
13,14
 There is precedent from work on other 
diiridium complexes that a rigid polymer matrix such as the 
cycloolefin polymer zeonex could also lead to a similar 
emission enhancement.
17
 
This property could be anticipated for complex 5 which 
does not feature rigidifying intramolecular interactions to 
restrict bridge motion.
13,26,48,49
 However, it is more surprising 
for 6–8, for which intramolecular π–π interactions are 
observed in their solution 
19
F NMR spectra (Figure 3) (similar 
to complex 4, Figure 1).  The non-emissive nature of complexes 
6–8 in solution could be related to their high triplet energies 
(ET) (≥ 2.70 eV), as we have previously noted that 
intramolecular π–π interactions become less effective at 
suppressing the non-radiative decay of hydrazide-bridged 
diiridium complexes in solution as their emission energies 
increase.
26
 
Figure 7. Emission spectra for THF solutions of complexes 6 and 8 upon 
incremental titration of water to induce precipitation (λexc 355 nm). THF 
fraction is percentage volume. 
 The emission spectra of 5–8 at 77 K in 2-MeTHF are 
relatively broad and show distinct vibronic features. Minimal 
rigidochromic shifts are observed on cooling (≤ 3 nm) 
compared to the room temperature emission spectra recorded 
in PMMA. This implies a strong LC contribution to the excited 
states of 5–8.
50
 The Huang-Rhys factors (SM) (estimated from 
the ratio of the v0,0 and v0,1 band intensities
51,52
) are also large: 
5 = 0.8, 6 = 0.8, 7 = 1.0 and 8 > 1.0 (1 s.f.). These values imply 
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that the excited states of 5–8 are highly distorted compared to 
their ground states,
45
 and are related to their non-emissive 
properties in solution. Comparing these data with those 
obtained for previous complexes,
13,26
 there is a rational inverse 
relationship between the Huang-Rhys factor and the solution 
PLQY for hydrazide-bridged diiridium complexes.  Complexes 
with SM values of < 0.5 (e.g complex 4) tend to be highly 
emissive (PLQY = ≥ 50%), those that are non-emissive in 
solution (e.g. 5−8) have SM values ≥ 0.7, and those that are 
weakly emissive (PLQY = ca. 1–5%) have intermediary SM 
values of 0.5–0.7.  
The PLQY of 5 in PMMA is notably lower than for 6–8 (11 ± 
10% vs. ca. 50 ± 10%). This is ascribed to an absence of 
rigidifying intramolecular π–π interactions in 5 as its      value 
is notably large (4.89 vs. 1.61 × 10
5 
s
−1
 for 6). The 
phosphorescence lifetimes of 6–8 are long for blue-green 
iridium phosphors.
53–57
 For example, while 6 has a very similar 
ET to the Hppy-derived complex 4 (2.70 vs. 2.72 eV) and a 
similar PLQY in PMMA (55 vs. 65 ± 10%), its   is over twice as 
long (2.80 μs for 6 vs. 1.19 μs for 4). This is related to the 
substantially lower    of 6 (1.96 × 10
5 
s
−1
 vs. 5.46 × 10
5 
s
−1
 for 
4) which is likely a consequence of a lower MLCT contribution 
to the excited state of 6. Therefore, the long phosphorescence 
lifetimes and low radiative rates of 5–8 are likely to stem from 
high LC contributions to their excited states. This is evident 
from the well-resolved vibronic features in their emission 
spectra recorded in PMMA at room temperature: the v0,0, v0,1, 
v0,2 and v0,3 bands are all reasonably well-resolved. This 
conclusion is also supported by minimal rigidochromic shifts in 
the emission spectra of 5–8 upon cooling (mentioned above). 
Blue shifting the emission in the series 6–8 through 
fluorination of the cyclometalating ligands of 7 and 8 also leads 
to incremental increases in   (i.e. for 8   = 4.55 μs and    = 
1.96 × 10
5 
s
−1
). This fits a typical trend in Ir(III) phosphors, 
where the LC character of the excited state increases upon 
blue shifting the emission.
29,58,59
 
Complexes 5–8 are emissive under UV irradiation (365 nm) 
in the solid state as powders. Typical aggregation-induced 
phosphorescent emission (AIPE) behaviour
47,60
 is observed by 
titrating water into THF solutions of the complexes to induce 
precipitation/ aggregation, which promotes emission. The 
emission intensity increases as the THF fraction decreases. 
Spectra for complexes 6 and 8 are shown in Figure 7. Spectra 
for 5 and 7 are included in Figure S3. The mechanism which 
results in solid state emission from 5–8 is, in principle no 
different from that which promotes emission in dilute PMMA 
films, as evident from near-identical spectral profiles. In the 
solid state intramolecular motion is restricted due to 
interactions between neighbouring complexes, rather than 
between the complexes and a PMMA host. This property is 
enabled by the bulky (and ancillary – see DFT below) mesityl 
groups. In the solid state they increase the distances between 
the emissive ‘cores’ of the complexes, suppressing triplet-
triplet annihilation as a quenching pathway (which dominates 
for unshielded diiridium complexes
13,61,62
). Complexes 5–8 
greatly extend the spectral range of diiridium AIPE emitters – 
the most prominent literature examples are orange/ red
14,23
 
while 8 is sky-blue (CIExy = 0.18, 0.27 in PMMA). 
 
Computational study 
Electronic structure calculations were carried out on 5–8 at the 
B3LYP/LANL2DZ:3–21G* level
12,13,19,26
 to gain insight into the 
photophysical properties of the complexes. In the optimised 
structures of 5–8 the central hydrazide fragments are 
predicted to be close to planar for both the meso and rac 
diastereomers. This contrasts with previously reported 
analogues,
12,13,26
 for which the rac forms tend to be folded, 
and is assigned to the highly congested nature of the 
structures. The optimised structures of meso 7 and meso 8 are 
in good agreement with the X-ray data. However, the 
optimised geometries of the rac forms of 5–8 cannot be 
compared with X-ray data as no rac structures have been 
solved. Such similar optimised geometries for the rac and 
meso diastereomers of 6–8 may explain why they could not be 
separated.  
 
Figure 8. Molecular orbital compositions for meso 5–8. The orbital 
contributions are percentages and the HOMO and LUMO energies were 
calculated at B3LYP/LANL2DZ:3–21G*. Bridge = central bridge OCNNCO 
fragment; F5 = fluorinated bridge aryl rings; Ph = cyclometalating ligand 
phenyl groups; Im = cyclometalating ligand imidazolyl groups. 
The predicted frontier molecular orbital (FMO) 
contributions are listed in Tables S2 and S3.  Generally, there is 
a good agreement between diastereomers, and so FMO plots 
for meso 5–8 are presented in Figure 8. (The FMO plots for the 
rac diastereomers are included in Figures S4 and S5). For the 
diastereomers of 5, the HOMOs are primarily localised on the 
Ir centres and the cyclometalating ligands, with some 
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contribution from the central hydrazide fragments of the 
bridging ligands, while the LUMOs are cyclometalating ligand-
based. The spatial separation of the FMOs on the 
cyclometalating ligands is less defined than for typical Hppy-
based complexes,
45,52,63
 i.e. the LUMO contribution is split 
nearly equally between the phenyl and imidazole moieties. 
This is in good agreement with studies on mononuclear 
complexes with similar 1,2-diarylimidazole  cyclometalating 
ligands.
40–42
 
For 6–8 the HOMOs are mainly localised on the Ir centres 
and the central hydrazide fragments of the bridging ligands. 
Interestingly, rather than being based on the cyclometalating 
ligands, the LUMOs are primarily localised on the bridge 
pentafluorophenyl groups for 6–8. This contrasts with the data 
reported for Hppy-based analogues such as 4, for which the 
pentafluorophenyl groups are ancillary.
26
 Presumably, this is 
due to the more electron rich nature of the imidazole 
heterocycles compared to pyridine, which forces the LUMO 
onto the strongly electron accepting pentafluorophenyl 
groups. As a result, the cyclometalating ligands of 6–8 are not 
major FMO contributors (their HOMO and LUMO contributions 
are ≤ 20%). Nevertheless, complexes 6–8 are emissive despite 
their unusual FMO distributions, highlighting the versatility of 
hydrazide bridges as a platform for obtaining emissive 
diiridium complexes. 
To determine the significance of the unusual FMO 
distributions of 6–8, a time-dependent density functional 
theory (TD-DFT) study was carried out to gain insight into the 
nature of their lowest energy excited states. This is because a 
simple consideration of the FMOs is not necessarily sufficient 
to predict the localisation of the lowest energy triplet states of 
Ir(III) complexes.
64–66
  The data for both diastereomers of the 
least (6) and most (8) fluorinated derivatives are presented in 
Table 4 (the data for 7 show the same trends and are included 
in Table S4). The two largest contributing transitions to each 
state (≥ ca. 20%) are included. The TD-DFT data for 5 are 
included in Table S4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Summary of the TD-DFT data for complexes 6 and 8. 
Transition 
6 8 
meso rac meso rac 
Main orbital contribution λ/ 
nm  
Main orbital contribution λ/ 
nm  
Main orbital contribution λ/ 
nm  
Main orbital contribution λ/ 
nm  
S0 → T1 HOMO → LUMO 429 HOMO-1-→-LUMO+3, 
HOMO-→ LUMO+1 
426 HOMO → LUMO 420 HOMO-1-→ LUMO+3 409 
S0 → T2 HOMO-2-→-LUMO+3, 
HOMO-→ LUMO+1 
425 HOMO-1-→-LUMO+1, 
HOMO-→ LUMO+3 
425 HOMO-→ LUMO+1 410 HOMO-1-→-LUMO+2, 
HOMO-→ LUMO+3 
409 
S0 → T3 HOMO-→ LUMO+3, HOMO-
2-→ LUMO+2 
423 HOMO-1-→-LUMO+4, 
HOMO-2-→ LUMO+1 
417 HOMO-→ LUMO+3, HOMO-
2-→ LUMO+1 
408 HOMO-1-→-LUMO+4, 
HOMO-2-→ LUMO+5 
403 
S0 → T4 HOMO-1-→ LUMO+2 416 HOMO-2-→ LUMO+4 417  HOMO-1-→-LUMO+4, 
HOMO-2-→ LUMO+2 
402 HOMO-2-→ LUMO+4 403  
S0 → T5 HOMO-1-→ LUMO+4 415  HOMO-→ LUMO+17 413  HOMO-1-→-LUMO+2, 
HOMO-2 → LUMO+4 
401 HOMO-→ LUMO+8 402 
 
Both diastereomers of 6–8 feature 5 triplet states that are 
relatively close in energy (≤ 20 nm). A number of these states may, 
therefore, be relevant when considering their emissive states.
64
 
Such a large number of near-degenerate states, many of which 
have significant contributions from multiple transitions, complicates 
detailed analysis of the data. However, it can be noted that as well 
as a HOMO → LUMO transition, many of the relevant transitions in 
Table 4 involve contributions from higher energy unoccupied 
(LUMO+1 – LUMO+3), and lower energy occupied (HOMO−1 and 
HOMO−2) orbitals. Contributions for the HOMO−5 – LUMO+5 
orbitals are tabulated in Tables S2 and S3. Particularly, while the 
LUMO+2 and LUMO+3 orbitals of 6–8 generally include a degree of 
pentafluorophenyl character, their cyclometalating ligand character 
is much higher than for the LUMOs (≥ 50%, as high as 100%). Also, 
the HOMO−1 and HOMO−2 orbitals for 6–8 are almost exclusively 
distributed between the Ir atoms and cyclometalating ligands (ca. 
50:50 in all cases), in contrast to the HOMO orbitals that are mainly 
Ir and hydrazide based. Therefore, while it is likely that the 
pentafluorophenyl substituents are somewhat involved in the 
excited states of 6–8, TD-DFT predicts that the cyclometalating 
ligands are more involved in their emitting states than is implied by 
a simple FMO analysis.
35,40
 This analysis is in agreement with the 
photophysical data above. For example, the observation that the 
profiles of the PL spectra for 6–8 are very similar to those of 
homoleptic 2-phenylimidazole complexes
30,33–38
 (which do not 
feature bridging ligands) signifies that their excited states should 
possess a high degree of LC character on the cyclometalating 
ligands. 
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Conclusions 
A new family of hydrazide-bridged diiridium complexes 5–8 
based on bulky 1,2-diarylimidazole cyclometalating ligands has 
been studied in detail.  
The complexes 6–8 are strongly emissive when doped into 
PMMA. Significantly emissive ppy-free diiridium complexes are 
rare, and of these 6–8 exhibit the highest PLQYs yet reported 
(ΦPL = 47–55 ± 10%).
23,31
 They display emission peaks as blue 
shifted as 452 nm and complex 8 has CIExy colour coordinates 
in the sky-blue region (0.18, 0.27). Prior to this work there 
have been only two reports of sky-blue diiridium 
complexes,
22,26
 both containing Hppy ligands. We have shown, 
therefore, that Hppy is not essential for obtaining highly 
emissive diiridium complexes, and also Hppy is not required 
for the challenging task of shifting their emission into the sky-
blue region.  Moreover, complex 8 is as blue as the bluest 
mono-Ir complexes yet reported based on arylimidazole 
ligands.
35,38
  
X-ray crystallography and solution-state 
19
F NMR spectra 
reveal the presence of rigidifying intramolecular π–π 
interactions for complexes 6–8, which explains their improved 
PLQYs compared to 5. The rather long phosphorescence 
lifetimes of 6–8 have been attributed to the high 
3
LC character 
of their excited states, which is corroborated by TD-DFT. 
The complexes also display AIPE behaviour. This 
substantially broadens the colour range that can now be 
accessed by AIPE diiridium emitters towards the sky-blue and 
should provide added versatility in applications such as anti-
counterfeiting.
67
 This study considerably increases the scope of 
dinuclear Ir(III) complexes to include luminophoric ligands that 
are not restricted to Hppy-type cyclometalates, and provides a 
foundation for further diversification of emissive diiridium 
complexes away from conventional Hppy architectures.  
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Experimental Section  
General  
1H, 13C and 19F NMR spectra were recorded on Bruker Avance 400 MHz, Varian Mercury 200, and 400 MHz, 
Varian Inova 500 MHz or Varian VNMRS 600 and 700 MHz spectrometers.  All spectra were either referenced 
against the residual solvent signal or tetramethylsilane (TMS) and peak shifts are reported in ppm. For 13C NMR 
assignment the labels * and # denote 2 and 3 overlapping signals, respectively. Electrospray ionisation (ESI) mass 
spectra were recorded on a Waters Ltd. TQD spectrometer. Atmospheric solids analysis probe (ASAP) mass spectra 
were recorded on a LCT premier XE spectrometer. Matrix-assisted laser desorption time-of-flight (MALDI–TOF) 
mass spectra were recorded on a Bruker Daltonik Autoflex II spectrometer running in positive ion reflectron mode. 
MALDI–TOF samples were prepared in CH2Cl2 (DCM) with trans-2-[3-(4-tert-butylphenyl)-2-methyl-2-
propenylidene]malononitrile (DCTB) as the matrix. Elemental analyses were obtained on an Exeter Analytical Inc. 
CE-440 elemental analyser. Thermal analysis was run under a helium atmosphere at a rate of 10 °C min−1 using a 
Perkin-Elmer Pyris 1 instrument. Reactions requiring an inert atmosphere were carried out under argon which was 
first passed through a phosphorus pentoxide column. Thin layer chromatography (TLC) was carried out on silica 
gel (Merck, silica gel 60, F254) or alumina (Merck, neutral alumina 60 type E, F254) plates and visualised using 
UV light (254, 315, 365 nm). Flash chromatography was carried out using either glass columns or a Biotage® 
Isolera OneTM automated flash chromatography machine on 60 micron silica gel purchased from Fluorochem Ltd.  
Chemicals 
All commercial chemicals were of ≥95% purity and were used as received without further purification. N-(2,2-
Diethoxyethyl)mesitylamine (S1),1 bis(trifluoromethyl)hydrazide (2H13) and N,Nʹ-
bis(pentafluorobenzoyl)hydrazide (2H12)2 were prepared by literature procedures.  All solvents used were of 
analytical reagent grade or higher. Anhydrous solvents were dried through a HPLC column on an Innovative 
Technology Inc. solvent purification system or purchased from Acros (dry diglyme). 
Calculations 
All calculations were carried out with the Gaussian 09 package.3 All optimised S0 geometries of the diiridium 
complexes were carried out using B3LYP4,5 with the pseudopotential (LANL2DZ)6–8 for iridium and 3–21G* basis 
set for all other atoms.9,10 All S0 geometries were true minima based on no imaginary frequencies found. Electronic 
structure calculations were also carried out on the optimised geometries at B3LYP/LANL2DZ:3–21G*. The MO 
diagrams and orbital contributions were generated with the aid of Gabedit11 and GaussSum12 packages, 
respectively. 
X-ray Crystallography 
X-ray diffraction experiments were carried out at 120 K on a Bruker 3-circle diffractometer D8 Venture with a PHOTON 
100 CMOS area detector, using Mo-Kα radiation from an Incoatec IμS microsource with focussing mirrors and a Cryostream 
(Oxford Cryosystems) open-flow N2 gas cryostat. The absorption correction was carried out by numerical integration based 
on crystal face indexing, using SADABS program.13 The structures were solved by Patterson or direct methods using 
SHELXS 2013/1 software14 and refined in anisotropic approximation by full matrix least squares against F2 off all data, 
using SHELXL 2018/3 software15 on OLEX216  platform. In both structures, the asymmetric unit comprises half of the 
complex molecule (which possesses a crystallographic inversion centre), as well as three DCM molecules (meso-7) or one 
methanol molecule (meso-8). Crystal data are listed in Table S5.  
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Electrochemistry 
Cyclic voltammetry experiments were recorded using either BAS CV50W electrochemical analyzer or a a 
PalmSens EmStat2 potentiostat with PSTrace software. A three-electrode system consisting of a Pt disk (Ø = 1.8 
mm) as the working electrode, a Pt wire as an auxiliary electrode and an Pt wire as a quasireference electrode was 
used. Cyclic voltammetry experiments were conducted at a scan rate of 100 mV/s. Experiments were conducted in 
dry, degassed DCM with n-Bu4NPF6 (0.1 M) as the supporting electrolyte for oxidations, and in dry, degassed THF 
with n-Bu4NPF6 (0.1 M) as the supporting electrolyte for reductions. All experiments were referenced internally to 
ferrocene. Oxidation processes are assigned as being electrochemically reversible based on the equal magnitudes of 
corresponding oxidation and reduction peaks. 
Photophysics 
General. The absorption spectra were measured on either a Unicam UV2-100 spectrometer operated with the Unicam 
Vision software or a Thermo Scientific Evolution 220 spectrometer with the Thermo Scientific Insight software in quartz 
cuvettes with a path length of 20 mm. The pure solvent was used for the baseline correction. The extinction coefficients were 
calculated using the Beer-Lambert Law, A = εcl. They were measured using a titration method, whereby a stock solution of 
known concentration was incrementally added using a calibrated glass pipette to a cuvette of pure solvent. A minimum of 1 
mg of sample was weighed for the stock solutions, and the measurements were carried out in triplicate to minimise weighing 
and dilution-errors. The photoluminescence spectra were recorded on a Horiba Jobin Yvon SPEX Fluorolog 3-22 
spectrofluorometer in quartz cuvettes with a path length of 10 mm. All Ir complexes were measured in degassed DCM 
(repeated freeze-pump-thaw cycles using a turbomolecular pump). The quantum yields of all samples were determined by 
the comparative method relative to quinine sulphate in 0.5 M H2SO4 (Φ = 0.546
17) following the literature procedure.18 
Poly(methyl methacrylate) films were prepared according to a literature procedure.2 The quantum yields of complexes doped 
in PMMA thin films were recorded on a Horiba Jobin Yvon SPEX Fluorolog 3 using a calibrated Quanta-Φ integrating 
sphere and were calculated according to the literature method.19 Solid state PLQY data were obtained in triplicate from three 
samples that were prepared in parallel: the calculated standard error values were ≤10%. Lifetime measurements were 
recorded using an N2 laser (337 nm, 10 μJ, 10 Hz) as an excitation source in a custom spectrometer which produced a 1 kHz 
train of pulses of 20 ns duration. The luminescence was collected at 90° and focused onto the entrance slit of a 
monochromator (Bethan TM 300V). The emission was detected by a photon counting PMT and the arrival times of photons 
at the detector determined using a multichannel scaler.  The data were transferred to a PC and analysed using non-linear 
regression. The decay data were fitted to exponential functions. Low temperature emission spectra and lifetime data were 
measured in a DN1704 optical cryostat (Oxford Instruments) with a ITC601 temperature controller (Oxford Instruments). 
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Synthesis 
General procedure for the synthesis of 1,2-diarylimidazoles (H9–H11). Based on a literature procedure.20 
Step I. Based on ca. 10 mmol scale of N-(2,2-diethoxyethyl)mesitylamine (S1). Triethylamine (2.00 eq.) and the 
benzoyl chloride derivative (5.00 eq.) were added sequentially to a solution of N-(2,2-diethoxyethyl)mesitylamine 
(S1) (1.00 eq.) in DCM (20 mL) under argon at 0 °C. The mixture was warmed to room temperature and stirred 
overnight. The solvent was then removed under reduced pressure and the residue was dissolved in acetone/ water 
(9:1 v/v, 20 mL). para-Toluenesulfonic acid (2.10 eq.) was added and the resulting mixture was heated to reflux for 
2 h. The solvent was evaporated under reduced pressure and the residue was dissolved in EtOAc (80 mL). The 
solution was washed with sat. aq. Na2CO3 (2 × 50 mL). The washings were combined and extracted with EtOAc (3 
× 80 mL). All organic layers were then combined, washed with water (20 mL), dried over MgSO 4 and filtered. 
After evaporation of the solvent, the residue (A) was used in Step II without further purification. 
Step II. The product (A) from Step I was cautiously dissolved in acetic anhydride (15 mL). The solution was 
cooled to 0 °C and aq. HBF4 (50%, 1.20 eq.) was added slowly. The resulting mixture was stirred overnight at room 
temperature. It was then added dropwise to stirred diethyl ether (100 mL) to precipitate the intermediate salt B. 
Prolonged stirring, sonication or scratching was sometimes required to induce precipitation. The solid was filtered 
and washed with Et2O (2 × 10 mL). 
Step III. The product (B) from Step II was dissolved in MeCN (30 mL). NH4OAc (1.70 eq.) was added and the 
solution was stirred at room temperature for 24 h. Next, aq. HBF4 (50%, 1.70 eq.) was added and the reaction 
mixture was heated to reflux overnight. The solvent was evaporated under reduced pressure and the residue was 
dissolved in EtOAc (80 mL). The solution was washed with sat. aq. Na2CO3 (2 × 50 mL). The washings were 
combined and extracted with EtOAc (3 × 80 mL). All organic layers were then combined, washed with water (20 
mL), dried over MgSO4 and filtered. After evaporation of the solvent the residue was purified by flash 
chromatography on silica gel. 
1-(2,4,6-Trimethylphenyl)-2-phenylimidazole (H9).  The general procedure for 1,2-diarylimidazoles was 
followed starting from N-(2,2-diethoxyethyl)mesitylamine (S1) (6.63 g, 26.4 mmol, 1.00 eq.) 
and benzoyl chloride (18.6 g, 132 mmol, 5.00 eq.). The crude product was purified by flash 
chromatography on silica gel (eluent: gradient 1:0–6:4 n-hexane/ EtOAc v/v with ca. 0.5% 
NEt3 as additive) to obtain 1-(2,4,6-trimethylphenyl)-2-phenylimidazole (H9) as an off-white 
powder (4.40 g, 16.7 mmol, 63%). NMR analytical data were in agreement with those 
previously reported.20 1H NMR (400 MHz, CDCl3) δ (ppm) = 7.46 – 7.41 (m, 2H), 7.33 (d, J = 1.2 Hz, 1H), 7.26 – 
7.20 (m, 3H), 6.99 – 6.96 (m, 2H), 6.91 (d, J = 1.2 Hz, 1H), 2.37 (s, 3H), 1.94 (s, 6H). 
1-(2,4,6-Trimethylphenyl)-2-(4-fluorophenyl)imidazole (H10).  The general procedure for 1,2-diarylimidazoles 
was followed starting from N-(2,2-diethoxyethyl)mesitylamine (S1) (3.17 g, 12.6 mmol, 1.00 
eq.) and 4-fluorobenzoyl chloride (10.0 g, 63.0 mmol, 5.00 eq.). The crude product was 
purified by flash chromatography on silica gel (eluent: gradient 1:0–6:4 n-hexane/ EtOAc v/v 
with ca. 0.5% NEt3 as additive) to obtain 1-(2,4,6-trimethylphenyl)-2-(4-
fluorophenyl)imidazole (H10) as an off-white powder (2.12 g, 7.56 mmol, 60%). M.pt. 107–
109 °C; 1H NMR (400 MHz, CDCl3) δ (ppm) = 7.43 – 7.37 (m, 2H), 7.31 (d, J = 1.3 Hz, 1H), 
6.98 (s, 2H), 6.96 – 6.88 (m, 3H), 2.37 (s, 3H), 1.93 (s, 6H); 13C NMR (101 MHz, CDCl3) δ (ppm) = 162.6 (d, J = 
248.4 Hz), 145.5, 139.0, 135.2, 134.4, 129.4, 129.3, 128.6 (d, J = 8.2 Hz), 127.0 (d, J = 3.4 Hz), 121.9, 115.4 (d, J 
= 21.6 Hz), 21.1, 17.6; 19F{1H} NMR (376 MHz, CDCl3) δ (ppm) = -113.1 (s, 1F); HRMS (ESI): m/z 281.1458 
[MH+]. Calcd. for C18H18FN2
+: 281.1454. 
1-(2,4,6-Trimethylphenyl)-2-(2,4-difluorophenyl)imidazole (H11).  A modification of the general procedure for 
1,2-diarylimidazoles was followed starting from N-(2,2-diethoxyethyl)mesitylamine (S1) 
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(3.33 g, 13.2 mmol, 1.00 eq.) and 2,4-difluorobenzoyl chloride (9.30 g, 66.0 mmol, 5.00 eq.) where aq. PF6 (65%, 
1.20 eq.) was used instead of aq. HBF4 in step II. The crude product was purified by flash chromatography on silica 
gel (eluent: gradient 1:0–4:6 n-hexane/ EtOAc v/v with ca. 0.5% NEt3 as additive) to obtain 1-(2,4,6-
trimethylphenyl)-2-(2,4-difluorophenyl)imidazole (H11) as an off-white powder (2.22 g, 7.39 mmol, 56%). M.pt. 
80.5–82 °C; 1H NMR (400 MHz, CDCl3) δ (ppm) = 7.37 (d, J = 1.3 Hz, 1H), 7.32 (td, J = 8.5, 6.4 Hz, 1H), 7.00 (d, 
J = 1.3 Hz, 1H), 6.89 (s, 2H), 6.82 (dddd, J = 8.7, 7.8, 2.5, 0.7 Hz, 1H), 6.74 (ddd, J = 10.2, 8.9, 2.5 Hz, 1H), 2.31 
(s, 3H), 1.96 – 1.93 (m, 6H); 13C NMR (101 MHz, CDCl3) δ (ppm) = 163.1 (dd, J = 251.7, 12.0 Hz), 160.3 (dd, J = 
254.4, 12.8 Hz), 142.2 (d, J = 2.5 Hz), 138.6, 135.1, 133.4, 132.4 (dd, J = 9.7, 4.1 Hz), 129.8, 129.1, 122.1, 115.6 
(dd, J = 14.4, 3.9 Hz), 111.4 (dd, J = 21.3, 3.9 Hz), 104.4 (t, J = 25.7 Hz), 21.0, 17.6; 19F{1H} NMR (376 MHz, 
CDCl3) δ (ppm) = -108.2 (dd, J = 8.8, 0.9 Hz, 1F), -108.4 (dd, J = 8.9, 1.1 Hz, 1F); HRMS (ESI): m/z 299.1363 
[MH+]. Calcd. for C18H17F2N2
+: 299.1360. 
Complex 5.  IrCl3·3H2O (250 mg, 0.71 mmol, 1.00 eq.) and 1-(2,4,6-trimethylphenyl)-2-phenylimidazole (H9) 
(390 mg, 1.49 mmol, 2.10 eq.) were added to 2-
ethoxyethanol (10 mL) and the mixture was heated 
to reflux under an argon atmosphere for 24 h to 
form the dichloro-bridged diiridium intermediate in 
situ. The reaction mixture was then cooled to room 
temperature before addition of N,Nʹ-
bis(trifluoromethyl)hydrazide (2H13) (79 mg, 0.35 
mmol, 0.50 eq.) and K2CO3 (147 mg, 1.06 mmol,  
1.49 eq.). The mixture was then heated at reflux for 
a further 24 h before being cooled to room 
temperature. The solvent was evaporated, and the 
residue was purified by flash chromatography on 
silica gel (eluent: gradient 1:1–0:1 n-hexane/ DCM sat. K2CO3). After removing the solvent under reduced 
pressure, the residue was dissolved in a minimal amount of DCM (ca. 10 mL). Addition of hexane (ca. 20 mL) 
followed by reducing the volume of the mixture to 20 mL afforded complex 5 (400 mg, 0.24 mmol, 68%) as a light 
yellow precipitate which was isolated via filtration and washed with pentane. It was isolated as a single 
diastereomer. 1H NMR (700 MHz, CD2Cl2, TMS) δ (ppm) = 7.28 (d, J = 1.5 Hz, 2HA5), 7.22 (d, J = 1.5 Hz, 2HB5), 
7.11 – 7.07 (m, 10HA4, mesAr), 6.89 (d, J = 1.5 Hz, 2HB4), 6.61 (td, J = 7.5, 1.4 Hz, 2HC4), 6.54 (ddd, J = 8.1, 7.2, 1.4 
Hz, 2HD4), 6.49 (td, J = 7.5, 1.2 Hz, 2HC5), 6.43 – 6.41 (m, 4HD3, D5), 6.25 (dd, J = 7.5, 1.2 Hz, 2HC3), 6.14 – 6.12 
(m, 4HC6, D6), 2.41 (s, 6HmesMe), 2.41 (s, 6HmesMe), 2.13 (s, 6HmesMe), 2.08 (s, 6HmesMe), 1.96 (s, 6HmesMe), 1.95 (s, 
6HmesMe); 
19F NMR (376 MHz, CD2Cl2) δ (ppm) = -66.4 (s, 3F); 
13C NMR (176 MHz, CD2Cl2, TMS) δ (ppm) = 
157.9 (CA2), 157.1 (BB2), 146.5 (CD2), 144.3 (CC2), 140.0* (CmesAr), 135.8–135.7 (C4 × mesAr), 135.7 (CC1), 135.2 
(CD1), 133.8 (CD3), 133.0 (CmesAr), 132.8 (CmesAr), 132.2 (CC3), 129.4–129.3 (C4 × mesAr), 127.7 (CC4), 126.9* (CB5, 
D4), 125.1 (CA5), 121.0 (CC6 or D6), 120.7 (CC5), 120.6 (CC6 or D6), 119.8 (CA4, B4), 118.9 (CD5), 20.9* (CmesMe), 17.5* 
(CmesMe), 17.0* (CmesMe); MS (MALDI–TOF): m/z 1652.3 [M
+]. Calcd. for C76H68F6Ir2N10O2
+: 1652.5; Anal. Calcd. 
for C76H68F6Ir2N10O2: C, 55.26; H, 4.15; N, 8.48, Calcd. for C76H68F6Ir2N10O2∙0.5CH2Cl2: C, 54.23; H, 4.10; N, 
8.27. Found:  C, 54.40; H, 4.04; N, 8.34. Due to low solubility in organic solvents and coupling to 19F nuclei, the 
quarternary bridge 13C NMR signals were not observed. All signals that could be clearly identified in the 13C, 1H–
13C HSQC and 1H–13C HMBC NMR spectra are reported. Some of the aromatic mesityl 13C environments are 
reported as a range due to the large number of overlapping signals. 
General procedure for the synthesis of the diarylhydrazide-bridged complexes (6–8). IrCl3·3H2O (250 mg, 
0.71 mmol, 1.00 eq.) and the 1,2-diarylimidazole cyclometallating ligand (1.49 mmol, 2.10 eq.) were added to 2-
ethoxyethanol (10 mL) and the mixture was heated to reflux under an argon atmosphere for 24 h to form the 
S6 
 
dichloro-bridged diiridium intermediate in situ. The reaction mixture was cooled to room temperature and the 
solvent was evaporated under reduced pressure. The residue was then dried under high vacuum. Next, N,Nʹ-
bis(pentafluorobenzoyl)hydrazide (2H12) (149 mg, 0.35 mmol, 0.50 eq.) and K2CO3 (147 mg, 1.06 mmol,  1.49 
eq.) were added and the mixture was suspended in dry diglyme (15 mL). It was then heated in a 120 °C heating 
mantle under argon overnight. The reaction was cooled to room temperature and the solvent was subsequently 
removed under reduced pressure. The residue was firstly purified by flash chromatography on silica gel (eluent: 
typically gradient n-hexane/ DCM sat. K2CO3) and then dissolved in minimal DCM (ca. 10 mL). Addition of 
hexane (ca. 20 mL) followed by reducing the volume of the mixture to 20 mL afforded the complexes as coloured 
precipitates which were isolated via filtration and washed with pentane.  
Complex 6. Prepared according to the general procedure, complex 6 was obtained as a light yellow powder (460 
mg, 0.25 mmol, 70%). The flash chromatography eluent 
was DCM sat. K2CO3. 6 was obtained as a diastereomeric 
mixture in a ca. 1:1 ratio. This complicates NMR 
assignment of the individual diastereomers making them 
very difficult to distinguish and so the overlapping spectra 
of the mixture are reported. 1H and 13C Signals are 
assigned based on whether they represent imidazole (A), 
phenyl (B) or mesityl (mes) environments. Coupling 
constants in 1H NMR are ± 0.5 Hz. 1H NMR (700 MHz, 
CD2Cl2, TMS) δ (ppm) = 7.64 – 7.62 (m, 2HA), 7.54 (d, J 
= 1.5 Hz, 2HA), 7.49 (d, J = 1.6 Hz, 2HA), 7.20 (d, J = 1.9 
Hz, 2HmesAr), 7.17 (d, J = 1.9 Hz, 2HmesAr), 7.13 (d, J = 
1.5 Hz, 2HA), 7.08 (dd, J = 9.6, 1.6 Hz, 10H2 × A, mesAr), 7.06 – 7.04 (m, 6HmesAr), 6.97 (d, J = 1.5 Hz, 2HA), 6.92 (d, 
J = 1.5 Hz, 2HA), 6.53 – 6.49 (m, 4H2 × B), 6.44 – 6.39 (m, 4H2 × B), 6.37 – 6.33 (m, 2HB), 6.33 – 6.28 (m, 8H4 × B), 
6.18 – 6.11 (m, 10H5 × B), 6.10 (dd, J = 7.7, 1.3 Hz, 2HB), 6.07 (dd, J = 7.8, 1.3 Hz, 2HB), 2.43 – 2.42 (m, 
12HmesMe), 2.40 (s, 6HmesMe), 2.40 (s, 6HmesMe), 2.37 (s, 6HmesMe), 2.27 (s, 6HmesMe), 2.08 (s, 6HmesMe), 2.06 (s, 
6HmesMe), 2.01 – 2.00 (m, 18HmesMe), 1.82 (s, 6HmesMe); 
19F {1H} NMR (376 MHz, CD2Cl2) δ (ppm) = -140.70 (dd, 
J = 24.7, 6.5 Hz, 2F), -141.89 (dd, J = 24.7, 7.2 Hz, 2F), -142.95 (dd, J = 24.5, 7.4 Hz, 2F), -143.87 (dd, J = 23.8, 
7.5 Hz, 2F), -158.1 – - 157.9 (m, 4F), -161.53 (td, J = 24.1, 22.4, 7.5 Hz, 2F), -162.14 (td, J = 24.2, 7.5 Hz, 2F), -
163.90 (td, J = 23.1,  7.6 Hz, 2F), -164.79 (td, J = 22.9, 7.2 Hz, 2F); 13C NMR (176 MHz, CD2Cl2, TMS) δ (ppm) = 
183.6* (CC=O), 157.5 (CA), 157.4 (CA), 157.3 (CA), 157.0 (CA), 148.5 (CB), 148.0 (CB), 147.3 (CB), 146.9 (CB),  
139.7 (C4 × mesAr), 136.1* (CB), 135.8 (C4 × mesAr), 135.6 (C4 × mesAr), 134.8 (CB), 134.6 (CB), 132.9 (C4 × mesAr, 2 × B), 
132.5 (C2 × B) 129.5* (CmesAr), 129.4
# (CmesAr), 129.3
# (CmesAr), 127.5 (C2 × B), 127.2 (CB), 127.0 (CB), 126.7* (CA), 
125.5 (CA), 125.4 (CA), 120.9 (C4 × B), 120.8 (CB), 120.6* (CB), 120.5 (CA), 120.1 (CA), 119.8 (CA), 119.5 (CA), 
118.4 (CB), 20.9* (CmesMe), 20.8* (CmesMe), 17.9* (CmesMe), 17.3* (CmesMe), 16.9 (CmesMe), 16.8 (CmesMe), 16.6 
(CmesMe), 16.5 (CmesMe); MS (MALDI–TOF): m/z 1848.4 [M
+]. Calcd. for C86H68F10Ir2N10O2
+: 1848.5; Anal. Calcd. 
for C86H68F10Ir2N10O2: C, 55.90; H, 3.71; N, 7.58, Calcd. for C86H68F10Ir2N10O2∙0.3CH2Cl2: C, 55.33; H, 3.69; N, 
7.48. Found:  C, 55.32; H, 3.66; N, 7.46. Due to poor solubility in organic solvents and extensive coupling to 19F 
nuclei, the 13C environments corresponding to the pentafluorophenyl groups were not observed. All signals that 
could be clearly identified in the 13C, 1H–13C HSQC and 1H–13C HMBC NMR spectra are reported. 
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Complex 7.  Prepared according to the general procedure, complex 7 was obtained as a light yellow powder (420 
mg, 0.22 mmol, 62%). The flash chromatography 
eluent was DCM sat. K2CO3. 7 was obtained as a 
diastereomeric mixture in a ca. 1:0.6 ratio. MS 
(MALDI–TOF): m/z 1920.3 [M+]. Calcd. for 
C86H64F14Ir2N10O2
+: 1920.4; Anal. Calcd. for 
C86H64F14Ir2N10O2: C, 53.80; H, 3.36; N, 7.30, Calcd. 
for C86H64F14Ir2N10O2∙0.3CH2Cl2: C, 53.28; H, 3.35; N, 
7.20. Found:  C, 53.22; H, 3.27; N, 7.20. 
 
Major diastereomer: 1H NMR (700 MHz, CD2Cl2, 
TMS) δ (ppm) = 7.51 (d, J = 1.5 Hz, 2HA), 7.43 (s, 
2HB), 7.18 (s, 2HmesAr), 7.16 (d, J = 1.5 Hz, 2HA), 7.09 
– 7.05 (m, 6H3 × mesAr), 6.93 (d, J = 1.5 Hz, 2HB), 6.18 – 6.05 (m, 8H2 × C, 2 × D), 5.87 (dd, J = 10.2, 2.6 Hz, 2HC), 
5.80 – 5.77 (m, 2HD), 2.43 (s, 6HmesMe), 2.39 (s, 6HmesMe), 2.24 (s, 6HmesMe), 2.07 (s, 6HmesMe), 2.01 (s, 6HmesMe), 
1.81 (s, 6HmesMe); 
19F NMR (376 MHz, CD2Cl2) δ (ppm) = -113.13 (d, J = 1.4 Hz, 2F), -113.35 (d, J = 1.4 Hz, 2F), 
-141.74 (dd, J = 24.5, 7.6 Hz, 2F), -142.60 (dd, J = 23.4, 7.6 Hz, 2F), -157.4 – -157.5 (m, 2F), -161.29 (td, J = 24.5, 
7.6 Hz, 2F), -163.90 (td, J = 22.7, 7.9 Hz, 2F); 13C NMR (176 MHz, CD2Cl2, TMS) δ (ppm) = 162.6 (C!), 161.3 
(C!), 156.7 (CA), 156.8 – 156.4 (C!), 156.2 (CB), 151.7 – 150.3 (C!), 139.9* (CmesAr), 135.9 – 135.5 (C4 × mesAr), 
132.5* (CmesAr), 132.2 (C!), 131.0 (C!), 129.7 – 129.5 (C4 × mesAr), 126.4 (CB), 125.2 (CA), 120.8 (CA), 119.8 (CB), 
118.6 (CC + D), 108.0 – 107.5 (C!), 105.6 – 105.4 (C!), 20.9* (CmesMe), 18.0 (CmesMe), 17.3 (CmesMe), 16.5* (CmesMe). 
 
Minor diastereomer: 1H NMR (700 MHz, CD2Cl2, TMS) δ (ppm) = 7.57 (d, J = 1.5 Hz, 2HA), 7.21 (s, 2HmesAr), 
7.09 (d, J = 1.5 Hz, 2HA), 7.09 – 7.05 (m, 6H3 × mesAr), 7.04 (d, J = 1.5 Hz, 2HB), 6.98 (d, J = 1.5 Hz, 2HB), 6.18 – 
6.05 (m, 8H2 × C, 2 × D), 5.80 – 5.77 (m, 2HD), 5.71 (dd, J = 10.1, 2.6 Hz, 2HC), 2.43 (s, 6HmesMe), 2.40 (s, 6HmesMe), 
2.35 (s, 6HmesMe), 2.05 (s, 6HmesMe), 2.01 (s, 6HmesMe), 1.99 (s, 6HmesMe); 
19F NMR (376 MHz, CD2Cl2) δ (ppm) = -
113.33 (s, 2F), -113.46 (s, 2F), -140.57 (dd, J = 24.2, 6.8 Hz, 2F), -143.33 (dd, J = 23.0, 6.0 Hz, 2F), -157.4 – -
157.5 (m, 2F),  -160.83 (td, J = 24.7, 8.0 Hz, 2F), -164.37 (td, J = 21.4, 7.3 Hz, 2F); 13C NMR (176 MHz, CD2Cl2, 
TMS) δ (ppm) = 162.6 (C!), 161.3 (C!), 156.8 – 156.4 (C!), 156.7 (CA), 156.4 (CB), 151.7 – 150.3 (C!), 139.2* 
(CmesAr), 135.9 – 135.5 (C4 x mesAr), 132.5* (CmesAr), 132.2 (C!), 131.0 (C!), 129.7 – 129.5 (C4 × mesAr), 126.4 (CA), 
125.2 (CB), 120.4 (CA), 120.1 (CB), 118.6 (CD), 118.1 (CC), 108.0 – 107.5 (C!), 105.6 – 105.4 (C!), 20.9* (CmesMe), 
18.0 (CmesMe), 17.3 (CmesMe), 16.8 (CmesMe), 11.9 (CmesMe). 
Due to poor solubility in organic solvents and extensive coupling to 19F nuclei, some quaternary 13C environments 
were not observed. As many of the signals corresponding to rings C and D heavily overlap in the 1H NMR 
spectrum of the diastereomeric mixture, their 13C environments could not be unambiguously assigned to a ring or 
diastereomer. Such signals/ regions are labelled “!”. All signals that could be clearly identified in the 13C, 1H–13C 
HSQC and 1H–13C HMBC NMR spectra are reported. Single crystals suitable for X-ray diffraction were grown by 
vapour diffusion of hexane into a DCM solution of the complex. 
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Complex 8.  Prepared according to the general procedure, complex 8 was obtained as a tan powder (334 mg, 0.17 
mmol, 47%). The flash chromatography eluent was 
gradient 9:1–4:6 n-hexane/ DCM sat. K2CO3 v/v. 
During precipitation the compound gelled, implying a 
propensity to interact with DCM. This is evident from 
the CHN result and residual DCM observed in the 1H 
NMR spectrum of the complex after drying. 8 was 
obtained as a diastereomeric mixture in a ca. 1:0.9 
ratio.  MS (MALDI–TOF): m/z 1992.1 [M+]. Calcd. for 
C86H60F18Ir2N10O2
+: 1992.4; Anal. Calcd. for 
C86H60F18Ir2N10O2: C, 51.86; H, 3.04; N, 7.03, Calcd. 
for C86H60F18Ir2N10O2∙1CH2Cl2: C, 50.31; H, 3.01; N, 
6.74. Found:  C, 50.31; H, 2.92; N, 6.79. 
 
Major diastereomer:  1H NMR (700 MHz, THF-d8) δ (ppm) = 7.66 (d, J = 1.5 Hz, 2HA5), 7.31 (d, J = 1.5 Hz, 
2HA4), 7.25 (d, J = 1.6 Hz, 2HB5), 7.11 (d, J = 2.0 Hz, 2HmesAr), 7.09 (d, J = 1.6 Hz, 2HB4), 7.00 (bs, 4HmesAr), 6.99 
(s, 2HmesAr), 6.01 (ddd, J = 11.3, 8.9, 2.4 Hz, 2HD4), 5.96 (ddd, J = 11.5, 9.0, 2.4 Hz, 2HC4), 5.64 (dd, J = 9.0, 2.4 
Hz, 2HD6), 5.58 (dd, J = 9.1, 2.4 Hz, 2HC6), 2.39 (s, 6HmesMe), 2.37 (s, 6HmesMe), 2.34 (s, 6HmesMe), 2.04 (s, 6HmesMe), 
2.02 –2.00  (m, 12HmesMe); 
19F{1H} NMR (376 MHz, THF-d8) δ (ppm) = -105.78 (d, J = 7.9 Hz, 2F), -106.45 – -
106.55 (m, 2F), -112.32 (d, J = 7.9 Hz, 2F), -112.70 – -112.80 (m, 2F), -141.07 (dd, J = 24.4, 6.4 Hz, 2F), -143.23 
(dd, J = 24.4, 7.1 Hz, 2F), -158.18 – -158.28 (m, 2F), -162.45 (td, J = 24.3, 7.4 Hz, 2F), -164.82 (td, J = 22.0, 21.5, 
7.1 Hz, 2F); 13C NMR (176 MHz, THF-d8) δ (ppm) = 164.3 (d, J = 250 Hz, CD5), 164.0 (d, J = 250 Hz, CC5), 159.0 
(d, J = 247 Hz, CC3), 158.2 (CA2), 158.0 (d, J = 264 Hz, CD3) 157.5 (CB2), 140.5* (CmesAr), 137.7 (CmesAr), 137.6 
(CmesAr), 137.5 (CmesAr), 137.0* (CmesAr), 136.7 (CmesAr), 130.6 (CmesAr), 130.3 (CmesAr), 130.2 (CmesAr), 130.1 
(CmesAr), 128.4 (CA5), 127.3 (CB4), 124.1 (CA4), 123.7 (CB5), 121.0 (CD2), 120.0 (CC2), 116.3 (d, J = 16.9 Hz, CD6), 
116.0 (d, J = 16.7 Hz, CC6), 98.0 (t, J = 25 Hz, CD4), 96.2 (t, J = 25 Hz, CC4), 22.0* (CmesMe), 19.1 (CmesMe), 18.5 
(CmesMe), 18.4 (CmesMe), 18.2 (CmesMe).  
 
Minor diastereomer: 1H NMR (700 MHz, THF-d8) δ (ppm) = 7.56 (d, J = 1.5 Hz, 2HA5), 7.51 (d, J = 1.7 Hz, 2HB5), 
7.39 (d, J = 1.5 Hz, 2HA4), 7.17 (d, J = 1.7 Hz, 2HB4), 7.12 – 7.10 (m, 2HmesAr), 7.08 (s, 2HmesAr), 7.00 – 6.97 (m, 
2HmesAr), 6.97 (s, 2HmesAr), 6.02 – 5.98 (m, 2HC4), 5.96 – 5.92 (m, 2HD4) 5.74 (dd, J = 9.2, 2.3 Hz, 2HD6), 5.61 (dd, 
J = 9.0, 2.4 Hz, 2HC6), 2.40 (s, 6HmesMe), 2.28 (s, 6HmesMe), 2.08 (s, 6HmesMe), 2.04 (s, 6HmesMe), 2.02 – 1.99 (m, 
6HmesMe), 1.86 (s, 6HmesMe); 
19F{1H} NMR (376 MHz, THF-d8) δ (ppm) = -105.71 (d, J = 8.0 Hz, 2F), -106.45 – -
106.55 (m, 2F), -111.87 (d, J = 8.0 Hz, 2F), -112.70 – 112.80 (m, 2F), -142.25 (dd, J = 24.7, 7.7 Hz, 2F), -142.54 
(dd, J = 24.7, 7.2 Hz, 2F), -158.18 – -158.28 (m, 2F), -162.72 (td, J = 23.7, 7.2 Hz, 2F), -164.12 (td, J = 23.7, 7.7 
Hz, 2F); 13C NMR (176 MHz, THF-d8) δ (ppm) = 164.4 (d, J = 250 Hz, CD5), 164.1 (d, J = 250 Hz, CC5), 159.3 (d, 
J = 245 Hz, CC3), 158.3 (d, J = 260 Hz, CD3), 157.7 (CA2 + B2), 140.6* (CmesAr), 137.9 (CmesAr), 137.6 (CmesAr), 137.5 
(CmesAr), 137.0* (CmesAr), 136.7 (CmesAr), 130.5 (CmesAr), 130.4 (CmesAr), 130.3 (CmesAr), 130.2 (CmesAr), 128.5 (CB5), 
127.3 (CA5), 124.4 (CA4), 123.6 (CB4), 120.9 (CC2), 120.0 (CD2), 116.3 (d, J = 17 Hz, CD6), 116.0 (d, J = 16 Hz, 
CC6), 98.0 (t, J = 27 Hz, CC4), 96.0 (t, J = 26 Hz, CD4), 21.90* (CmesMe), 19.1 (CmesMe), 18.5 (CmesMe), 18.1 (CmesMe), 
17.8 (CmesMe). 
Due to poor solubility in organic solvents and extensive coupling to 19F nuclei, some quaternary 13C environments 
were not observed (bridge carbons, C1 and D1). All signals that could be clearly identified in the 13C, 1H–13C 
HSQC and 1H–13C HMBC NMR spectra are reported. Single crystals suitable for X-ray diffraction were grown by 
vapour diffusion of methanol into a THF solution of the complex. 
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Copies of NMR Spectra 
 
Spectrum S1. 1H NMR spectrum (700 MHz) of 5 in CD2Cl2 (TMS).  
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Spectrum S2. 19F{1H} NMR spectrum (376 MHz) of 5 in CD2Cl2. 
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Spectrum S3. 13C NMR spectrum (151 MHz) of 5 in CD2Cl2 (TMS). 
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Spectrum S4. Expansion of the aromatic region of the 1H–1H COSY NMR spectrum of 5 in CD2Cl2 (TMS). 
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Spectrum S5. Expansion of the aromatic region of the 1H–13C HSQC NMR spectrum of 5 in CD2Cl2 (TMS). 
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Spectrum S6. Expansion of the aromatic region of the 1H–13C HMBC NMR spectrum of 5 in CD2Cl2 (TMS). 
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Spectrum S7. 1H NMR spectrum (700 MHz) of 6 in CD2Cl2 (TMS).  
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Spectrum S8. 19F{1H} NMR spectrum (376 MHz) of 6 in CD2Cl2. 
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Spectrum S9. 13C NMR spectrum (151 MHz) of 6 in CD2Cl2 (TMS). 
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Spectrum S10. Expansion of the aromatic region of the 1H–1H COSY NMR spectrum of 6 in CD2Cl2 (TMS). 
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Spectrum S11. Expansion of the aromatic region of the 1H–13C HSQC NMR spectrum of 6 in CD2Cl2 (TMS). 
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Spectrum S12. Expansion of the aromatic region of the 1H–13C HMBC NMR spectrum of 6 in CD2Cl2 (TMS). 
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Spectrum S13. 1H NMR spectrum (700 MHz) of 7 in CD2Cl2 (TMS).  
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Spectrum S14. 19F{1H} NMR spectrum (376 MHz) of 7 in CD2Cl2. 
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Spectrum S15. 13C NMR spectrum (151 MHz) of 7 in CD2Cl2 (TMS). 
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Spectrum S16. Expansion of the aromatic region of the 1H–1H COSY NMR spectrum of 7 in CD2Cl2 (TMS). 
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Spectrum S17. Expansion of the aromatic region of the 1H–13C HSQC NMR spectrum of 7 in CD2Cl2 (TMS). 
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Spectrum S18. Expansion of the aromatic region of the 1H–13C HMBC NMR spectrum of 7 in CD2Cl2 (TMS). 
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Spectrum S19. 1H NMR spectrum (700 MHz) of 8 in D8-THF.  
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Spectrum S20. 19F{1H} NMR spectrum (376 MHz) of 8 in D8-THF. 
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Spectrum S21. 13C NMR spectrum (151 MHz) of 8 in D8-THF. 
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Spectrum S22. Expansion of the aromatic region of the 1H–1H COSY NMR spectrum of 8 in D8-THF. 
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Spectrum S23. Expansion of the aromatic region of the 1H–13C HSQC NMR spectrum of 8 in D8-THF. 
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Spectrum S24. Expansion of the aromatic region of the 1H–13C HMBC NMR spectrum of 8 in D8-THF. 
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Spectrum S25. 1H NMR spectrum (400 MHz) of H10 in CDCl3.  
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Spectrum S26. 19F{1H} NMR spectrum (376 MHz) of H10 in CDCl3. 
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Spectrum S27. 13C NMR spectrum (101 MHz) of H10 in CDCl3. 
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Spectrum S28. 1H NMR spectrum (400 MHz) of H11 in CDCl3.  
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Spectrum S29. 19F{1H} NMR spectrum (376 MHz) of H11 in CDCl3. 
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Spectrum S30. 13C NMR spectrum (101 MHz) of H11 in CDCl3. 
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Electrochemistry 
 
 
Figure S1. Cyclic voltammograms in 0.1 M n-Bu4PF6/ THF showing the reduction process for complexes 5–8.
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Photophysics 
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Figure S2. Absorption spectra for complexes 5–8 recorded in aerated DCM at room temperature. 
 
Table S1. Tabulated absorption data for complexes 5–8 recorded in aerated DCM at room temperature. 
Complex λabs /nm (ε × 10
3 / M–1cm–1) 
5 258 (59), 288sh (34), 323 (21), 349 (16), 372 (9), 402 (5), 457 (0.3) 
6 260 (55), 287sh (34), 327 (16), 355 (12), 378sh (7.6), 459 (0.4) 
7 260 (51), 284sh (36), 315sh (20), 340 (14), 365sh (7.6), 384 (4.6), 442 (0.1) 
8 261 (52), 283sh (33), 315 (17), 338 (12), 360sh (6.9), 379sh (3.4), 443 (0.2) 
 
 
 
 
 
 
 
 
 
         
Figure S3. Emission spectra for THF solutions of complexes 5 and 7 upon incremental titration of water to induce 
precipitation (λexc 355 nm). THF fraction is percentage volume.
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Computations 
Table S2. Summary of the orbital contributions for complexes 5–7. 
 
 
 
 
 
 
 
 
 
 
 
 
a
Phenyl moieties of the cyclometalating ligands. 
b
Imidazole moieties of the cyclometalating ligands. 
 
 
 
 
 
 
Complex Isomer Orbital Ir 
Bridge 
centre 
Pha Imb 
105 
meso 
LUMO+5 3% 7% 35% 36% 
LUMO+4 0% 4% 4% 6% 
LUMO+3 1% 5% 4% 6% 
LUMO+2 3% 17% 28% 28% 
LUMO+1 3% 4% 43% 42% 
LUMO 3% 1% 49% 44% 
HOMO 45% 14% 33% 8% 
HOMO-1 47% 2% 40% 10% 
HOMO-2 48% 31% 13% 8% 
HOMO-3 63% 6% 18% 13% 
HOMO-4 45% 4% 28% 23% 
HOMO-5 43% 3% 29% 25% 
rac 
LUMO+5 1% 0% 6% 94% 
LUMO+4 1% 1% 6% 93% 
LUMO+3 1% 0% 8% 92% 
LUMO+2 1% 1% 14% 84% 
LUMO+1 3% 1% 44% 52% 
LUMO 2% 1% 43% 53% 
HOMO 46% 34% 13% 7% 
HOMO-1 49% 4% 40% 8% 
HOMO-2 42% 13% 35% 10% 
HOMO-3 64% 8% 14% 14% 
HOMO-4 40% 2% 31% 27% 
HOMO-5 61% 3% 19% 17% 
 
Complex Isomer Orbital Ir 
Bridge 
centre 
Bridge 
aryl 
Pha Imb 
106 
meso 
LUMO+5 1% 0% 10% 11% 13% 
LUMO+4 2% 1% 4% 29% 28% 
LUMO+3 3% 3% 30% 34% 27% 
LUMO+2 1% 1% 18% 42% 36% 
LUMO+1 4% 2% 57% 19% 17% 
LUMO 2% 7% 58% 17% 16% 
HOMO 44% 41% 1% 7% 7% 
HOMO-1 47% 7% 0% 37% 8% 
HOMO-2 47% 2% 1% 40% 10% 
HOMO-3 65% 7% 0% 14% 14% 
HOMO-4 45% 4% 1% 25% 25% 
HOMO-5 60% 5% 1% 16% 19% 
rac 
LUMO+5 2% 2% 16% 25% 54% 
LUMO+4 2% 0% 6% 32% 59% 
LUMO+3 2% 3% 40% 28% 26% 
LUMO+2 3% 3% 74% 10% 11% 
LUMO+1 2% 1% 1% 49% 46% 
LUMO 2% 3% 50% 23% 22% 
HOMO 44% 40% 1% 8% 7% 
HOMO-1 50% 3% 0% 38% 8% 
HOMO-2 44% 8% 0% 38% 10% 
HOMO-3 64% 9% 0% 13% 14% 
HOMO-4 42% 2% 1% 28% 27% 
HOMO-5 63% 2% 0% 17% 17% 
 
Complex Isomer Orbital Ir 
Bridge 
centre 
Bridge 
aryl 
Pha Imb 
107 
meso 
LUMO+5 2% 1% 16% 26% 27% 
LUMO+4 2% 1% 5% 36% 36% 
LUMO+3 1% 1% 13% 45% 38% 
LUMO+2 3% 2% 22% 38% 32% 
LUMO+1 4% 3% 68% 13% 12% 
LUMO 1% 9% 67% 11% 11% 
HOMO 43% 43% 1% 6% 7% 
HOMO-1 46% 5% 0% 38% 10% 
HOMO-2 45% 2% 1% 38% 14% 
HOMO-3 50% 4% 1% 23% 22% 
HOMO-4 48% 5% 1% 27% 19% 
HOMO-5 55% 5% 1% 20% 19% 
rac 
LUMO+5 3% 1% 5% 39% 36% 
LUMO+4 2% 2% 9% 36% 35% 
LUMO+3 3% 2% 24% 37% 31% 
LUMO+2 2% 2% 4% 47% 41% 
LUMO+1 3% 4% 78% 8% 7% 
LUMO 1% 4% 67% 14% 13% 
HOMO 43% 42% 1% 7% 7% 
HOMO-1 48% 3% 0% 37% 11% 
HOMO-2 41% 6% 0% 385 14% 
HOMO-3 60% 8% 0% 16% 15% 
HOMO-4 33% 2% 1% 35% 28% 
HOMO-5 53% 2% 1% 26% 18% 
5 6 7 
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Table S3. Summary of the orbital contributions for complex 8. 
 
a
Phenyl moieties of the cyclometalating ligands. 
b
Imidazole moieties of the cyclometalating ligands. 
 
 
 
 
 
 
 
Complex Isomer Orbital Ir 
Bridge 
centre 
Bridge aryl Pha Imb 
108 
meso 
LUMO+5 3% 1% 25% 36% 33% 
LUMO+4 4% 1% 1% 48% 44% 
LUMO+3 3% 3% 31% 34% 28% 
LUMO+2 1% 1% 18% 42% 36% 
LUMO+1 4% 2% 53% 21% 19% 
LUMO 2% 8% 56% 17% 17% 
HOMO 42% 45% 1% 5% 8% 
HOMO-1 47% 4% 0% 37% 11% 
HOMO-2 47% 3% 1% 35% 15% 
HOMO-3 47% 4% 1% 25% 24% 
HOMO-4 47% 5% 1% 27% 19% 
HOMO-5 49% 4% 1% 26% 20% 
rac 
LUMO+5 3% 3% 22% 37% 33% 
LUMO+4 4% 1% 10% 45% 38% 
LUMO+3 4% 2% 14% 41% 37% 
LUMO+2 3% 2% 2% 48% 43% 
LUMO+1 3% 2% 70% 13% 12% 
LUMO 1% 4% 71% 12% 11% 
HOMO 43% 44% 1% 6% 6% 
HOMO-1 50% 3% 0% 35% 12% 
HOMO-2 41% 5% 1% 37% 17% 
HOMO-3 56% 8% 0% 21% 14% 
HOMO-4 33% 2% 1% 32% 32% 
HOMO-5 50% 2% 1% 31% 16% 
8 
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Table S4. Summary of the TD-DFT data for complexes 5 and 7.  
 
 
Transition 
105 107 
meso rac meso rac 
Main orbital 
contribution 
λ/ 
nm 
(ƒ) 
Main orbital 
contribution 
λ/ 
nm 
(ƒ) 
Main orbital 
contribution 
λ/ 
nm 
(ƒ) 
Main orbital 
contribution 
λ/ 
nm 
(ƒ) 
S0 → T1 HOMO-2-→ 
LUMO+6, HOMO-2-
→ LUMO+8 
458 HOMO-→ 
LUMO+8  
460 HOMO → LUMO 424 HOMO-1-→ 
LUMO+3, HOMO-
→ LUMO+2 
415 
S0 → T2 HOMO-→ LUMO+1  425 HOMO-1-→ 
LUMO+1, HOMO-
→ LUMO 
425 HOMO-→ LUMO+1, 
HOMO-2-→ 
LUMO+2 
415 HOMO-1-→ 
LUMO+2, HOMO-
→ LUMO+3 
415 
S0 → T3 HOMO-1-→ LUMO 422 HOMO-1-→ 
LUMO,  
HOMO-→ 
LUMO+1 
425 HOMO-2-→ 
LUMO+3, HOMO-→ 
LUMO+2 
404 HOMO-→ 
LUMO+1, HOMO-
→ LUMO+16 
411 
S0 → T4 HOMO-→ LUMO+5, 
HOMO-→ LUMO+8 
417 HOMO-1-→ 
LUMO+2 
416  HOMO-2-→ 
LUMO+3, HOMO-1-
→ LUMO+4 
406 HOMO-1-→ 
LUMO+2, 
HOMO-1-→ 
LUMO+4 
407  
S0 → T5 HOMO-1-→ 
LUMO+2 
414  HOMO-2-→ 
LUMO+2, 
HOMO-1-→ 
LUMO+7 
416 HOMO-2-→ 
LUMO+4, HOMO-1-
→ LUMO+3 
406 HOMO-2-→ 
LUMO+2, 
HOMO-1-→ 
LUMO+5  
407 
         
 
5 7 
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Figure S4. Frontier molecular orbitals for the most stable minima of rac 5 and rac 6.  
 
Figure S5. Frontier molecular orbitals for the most stable minima of rac 7 and rac 8
rac 5 rac 6 
rac 7 rac 8 
S45 
 
Thermal Analysis 
 
Figure S6.TGA trace for complex 5. Onset = 404 °C 
S46 
 
 
Figure S7.TGA trace for complex 6. Onset = 401 °C 
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Figure S8.TGA trace for complex 7. Onset = 439 °C 
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Figure S9.TGA trace for complex 8. Onset = 437 °C.
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X-ray crystallography 
Table S5. Crystal data 
Compound  meso-7  meso-8 
CCDC dep. no. 1871136  1871137  
Formula  C86H64F14Ir2N10O2·6CH2Cl2 C86H60F18Ir2N10O2·2MeOH 
Dcalc./ g cm
-3
  1.706  1.687  
/mm-1  3.232  3.385  
Formula Weight  2429.42  2055.92  
Size/mm
3
  0.25×0.07×0.06  0.44×0.25×0.12  
T/K  120  120  
Crystal System  monoclinic  orthorhombic  
Space Group  C2/c (no. 15) Pbca  (no. 61) 
a/Å  24.2045(10)  20.0605(10)  
b/Å  14.8901(6)  13.1557(6)  
c/Å  27.9788(12)  30.6755(15)  
/°  110.265(2)  90  
V/Å
3
  9459.6(7)  8095.6(7)  
Z  4  4  
max/°  30.000  32.575  
Measured reflections  101919  175372  
Unique reflections  13754  14709  
Reflections with I > 2σ(I)  11072  11317  
Rint  0.0520  0.0536  
Parameters  616  576  
Residual Δρ, eÅ-3 3.04, -1.45  3.66, -1.60  
R1,wR2 [I > 2σ(I)] 0.0424, 0.1035  0.0378, 0.0738  
R1, wR2 (all data)  0.0612, 0.1125   0.0610, 0.0813   
Goodness of fit 1.079  1.077  
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